卵巢癌研究进展-国际医药研究前沿-CSCIED科技核心评价数据库-手机版

卵巢癌研究进展

Progress in ovarian cancer research

ES评分 0 浏览量：1013 下载量：0

DOI	10.12208/j.imrf.20220045
刊名	国际医药研究前沿 International Medical Research Frontier
年，卷(期)	2022, 6(2)
作者	李艳伟*,
作者单位	内蒙古医科大学内蒙古呼和浩特 ;
摘要	恶性肿瘤对人类健康的巨大威胁不言而喻。妇科肿瘤是世界各地女性死亡的主要原因之一。卵巢癌（ovarian cancer, OC）是一种多见的妇科恶性肿瘤。在妇科恶性肿瘤中死亡率位居第一，发病率位居第三。早期诊断的卵巢癌患者5年生存率较高。但早期的非特异性症状导致大多数患者发现时即晚期。目前治疗卵巢癌临床上多采用手术配合术后辅助化疗的方式。但晚期卵巢癌预后不良，5年生存率仍不到40%。众多研究者积极投身到卵巢癌的相关基础研究和临床研究中，并取得了非常显著的研究成果。本文就此对卵巢癌的相关研究进展进行综述，并对其联系进行讨论，以期可以为卵巢癌的发生、发展、治疗等方面提供有意义的可行的新思路。
Abstract	The great threat to human health of malignancy is self-evident.Gynecologic tumors are one of the leading causes of death in women around the world.Ovarian cancer (ovarian cancer, OC) is a common gynecological malignancy.Its incidence rate ranks the third among gynecological malignancies, but the mortality rate ranks the first.Patients with early diagnosed ovarian cancer have higher 5-year survival rates.But early unspecific symptoms are found late in most patients.At present, surgery and postoperative adjuvant chemotherapy are mostly used in the clinical treatment of ovarian cancer.However, advanced ovarian cancer has a poor prognosis, and the 5-year survival rate is still less than 40%.Many researchers have been actively engaged in the relevant basic research and clinical research of ovarian cancer, and have achieved very remarkable research results.This paper reviews the relevant research progress of ovarian cancer, and discusses its connection, in order to provide meaningful and feasible new ideas for the occurrence, development and treatment of ovarian cancer.
关键词	妇科肿瘤；卵巢癌；治疗；基础研究
KeyWord	Gynecological tumor; Ovarian cancer; Treatment; Basic research
基金项目
页码	15-19

参考文献
相关文献

[1] 刘晓宁,张明发,沈雅琴.和厚朴酚治疗妇科肿瘤的药理作用及其机制的研究进展[J].现代药物与临床,2022,37(06):1420-1424.
[2] 汤梓莹,邓明港,宇传华,刘晴.中国卵巢癌疾病负担现状及趋势分析[J].国际妇产科学杂志,2022,49(02):222-227.
[3] Lheureux S，Gourley C，Vergote I，et al. Epithelial ovarian cancer[J]. Lancet，2019，393(10177)：1240-1253.
[4] 陈琳,杨红.上皮性卵巢癌类器官的基础和转化研究进展[J/OL].中国肿瘤:1-5[2022-06-28].http://kns.cnki.net/kcms/detail/11.2859.R.20220623.1139.002.html
[5] Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma[J]. Ann Oncol,2013,24(Suppl 10):x16-x21
[6] Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013;24(suppl 10):x16-x21.
[7] Liu CL, Yuan RH, Mao TL. The Molecular Landscape Influencing Prognoses of Epithelial Ovarian Cancer. Biomolecules. 2021 Jul 7;11(7):998.
[8] Iida Y, Okamoto A, Hollis RL, et al. Clear Cell Carcinoma of the Ovary: A Clinical and Molecular Perspectiv [J]. Int J Gynecol Cancer 2021;31:605–616.
[9] Ku FC, Wu RC, Yang LY, et al. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study [J]. Formos Med Assoc. 2018;117(2):117-125.
[10] Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy[J]. Cancer. 2000;88(11):2584-2589.
[11] Okamoto A, Sehouli J, Yanaihara N, et al. Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma[J]. PLoS One. 2015;10(2):e0116977. doi:10.1371/journal.pone.0116977
[12] Iida Y, Okamoto A, Hollis RL, et al. Clear cell carcinoma of the ovary: a clinical and molecular perspective[J]. Int J Gynecol Cancer. 2021;31(4):605-616.
[13] Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma[J]. Cancer Sci. 2008;99(4):653-658.
[14] 靳成文,苏荣家.卵巢透明细胞癌研究进展[J].现代妇产科展,2020,29(12):947-949+952.
[15] Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers[J]. Gynecol Oncol. 2008;109(3):370-376.
[16] Iida Y, Okamoto A, Hollis RL, et al. Clear cell carcinoma of the ovary: a clinical and molecular perspective[J]. Int J Gynecol Cancer. 2021;31(4):605-616.
[17] Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary[J]. Am J Obstet Gynecol. 2011;205(5):480.
[18] Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16[J]. J Biol Chem. 2001;276(29):27371-27375.
[19] Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review[J]. Clin Pathol. 2013;66(4):273-281.
[20] 林燕玲,王瑛,黄颀,康灵,邢维珍,刘伟,黎先萍.血清miR-552-5p、HE4及CA125在上皮性卵巢癌中的表达及其临床价值[J].现代肿瘤医学,2022,30(13):2410-2414.
[21] Charkhchi P, Cybulski C, Gronwald J, et al. CA125 and Ovarian Cancer: A Comprehensive Review. Cancers (Basel). 2020;12(12):3730.
[22] Ma C. Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis[J]. World J Surg Oncol. 2022;20(1):154.
[23] Rossi L, Verrico M, Zaccarelli E, et al. Bevacizumab in ovarian cancer: A critical review of phase III studies[J]. Oncotarget. 2017;8(7):12389-12405.
[24] Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol. 2017;18(6):779-791.
[25] 杜钢军,时小燕.治疗癌症的新途径:靶向肿瘤微环境[J].国际药学研究杂志,2011,38(05):336-340.
[26] 殷爱军,李鹏,宋坤,姜洁,孔北华.安罗替尼在妇科肿瘤治疗中的现状及研究进展[J].现代妇产科进展,2022,31(05):384-388+393.
[27] 张琪琳,丁玉峰,戴冰,舒亚民.培美曲塞联合贝伐珠单抗维持治疗晚期非鳞状非小细胞肺癌成本-效果分析[J].中国药业,2022,31(10):106-111.
[28] 慈明伟,刘楠,高璐璐.奥希替尼+培美曲塞及贝伐单抗三联化疗对EGFR突变型NSCLC的疗效分析[J].国际医药卫生导报,2022,28(10):1418-1421.
[29] 王月,李蕾蕾,朱琳琳.贝伐珠单抗联合化疗治疗转移性结直肠癌对患者血清VEGF和TAP水平的影响[J].临床和实验医学杂志,2022,21(09):959-963.
[30] 益东晋.抗生素对贝伐珠单抗治疗转移性结直肠癌疗效的影响[J].中外医疗,2022,41(14):95-98+120.DOI:10.16662/j.cnki.1674-0742.2022.14.095.
[31] 张轶群,琚长斌,李芳,刘睿,程玉峰.非小细胞肺癌患者贝伐珠单抗相关不良反应临床分析[J].药物不良反应杂志,2022,24(05):233-238.
[32] Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. Hematol Oncol 11, 120 (2018). doi.org/10.1186/s13045-018-0664-7
[33] Sun L, Liu C, Li Y. Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma. Comput Math Methods Med. 2022;2022:4600145. Published 2022 Jun 10. doi:10.1155/2022/4600145
[34] Silk Ann W,Saraiya Biren,Groisberg Roman et al. A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.[J] .Eur J Med Res, 2022, 27: 107.
[35] Kennedy Fiona,Shearsmith Leanne,Holmes Marie et al. Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study.[J] .BMC Cancer, 2022, 22: 726.
[36] Nanthamongkolkul Kulisara,Wattanapaisal Panote,Boonyapipat Sathana et al. Appendiceal tumors in patients undergoing primary surgery for mucinous ovarian tumors in a tertiary hospital, in Southern Thailand.[J] .Taiwan J Obstet Gynecol, 2022, 61: 657-662.
[37] Lee Wen-Ling,Yang Szu-Ting,Wang Peng-Hui,Dehydroepiandrosterone (DHEA) adjuvant and poor ovarian responders.[J] .Taiwan J Obstet Gynecol, 2022, 61: 571-572.
[38] Bernard Juliette,Mehros Wala,Gregoire Jean et al. Low BRCA1/2 germline mutation rate in a French-Canadian population with a diagnosis of epithelial tubo-ovarian carcinoma.[J] .J Obstet Gynaecol Can, 2022, undefined: undefined.
[39] Motallebi Mahzad,Bhia Mohammed,Rajani Huda Fatima et al. Naringenin: A potential flavonoid phytochemical for cancer therapy.[J] .Life Sci, 2022, undefined: 120752.
[40] Fotopoulou Christina,Khan Tabassum,Bracinik Juraj et al. Outcomes of gynecological cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-GO Cancer study.[J] .Am J Obstet Gynecol, 2022, undefined: undefined.
[41] Zamani Fatemeh,Abdolrazaghnejad Aghdas,Ameli Fereshteh et al. Struma ovarii: A case report and review the literature.[J] .Int J Surg Case Rep, 2022, 96: 107318.

引用本文

李艳伟*. 卵巢癌研究进展 [J]. 国际医药研究前沿. 2022; 6; (2). 15 - 19.

文献评论

相关学者

相关机构